| Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. | |
| | |
MedLine Citation:
|
PMID: 8453694 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of > 150 mumol/l, a bilirubin level of > 20 mumol/l, a leukocyte cell count of < 3.5 x 10(9)/l, and a platelet count of < 100 x 10(9)/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy. |
| | |
Authors:
|
V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; J Verweij; P Dombernowsky; M Onsrud; D Thomas; R Sylvester |
Related Documents
:
|
7993844 - A phase ii trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with ma... 14581424 - Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous... 11669554 - Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refract... 19924514 - Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide ... 21494054 - Astragalosides reduce cisplatin ototoxicity in guinea pigs. 22941164 - Intraoperative diagnosis using sentinel node biopsy with indocyanine green dye in gastr... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 31 Suppl 2 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 1993 |
Date Detail:
|
Created Date: 1993-04-22 Completed Date: 1993-04-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: GERMANY |
Other Details:
|
Languages: eng Pagination: S180-4 Citation Subset: IM |
Affiliation:
|
London Regional Cancer Centre, Ontario, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Chi-Square Distribution Cyclophosphamide / adverse effects, therapeutic use* Female Humans Ifosfamide / adverse effects, therapeutic use* Leukopenia / chemically induced Male Middle Aged Sarcoma / drug therapy* Soft Tissue Neoplasms / drug therapy* Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
3778-73-2/Ifosfamide; 50-18-0/Cyclophosphamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Next Document: Ifosfamide combination regimens for soft-tissue sarcoma.